Workshop and Symposium Abstract Submissions Due
Oral and Poster Presentation Abstract Submissions Due
Scholarship Applications Due
Award Nominations Due
Presenters Confirm Participation
(Oral and Poster Presentations)
Presenter Registration Deadline
All Presenters Must Be Registered
Advanced Registration Deadline
ISOQOL Hotel Room Block Closes
This year’s conference will recognize 25 years of the International Society of Quality of Life Research, celebrate the achievements of the Society, and look ahead to the future of PRO development and application in research and practice.
We have a stimulating program featuring three plenary sessions that explore different aspects of PROs in today’s digital landscape.
Plenary 1: Digital self-tracking to support patient self-management
There is increasing interest in the digital collection and use of PRO data by patients to support self-management of long term conditions. In this plenary, we will explore the opportunities and challenges of digital self-tracking from different perspectives.
Plenary 2: Cutting Edge Research
The Cutting Edge Research plenary session will feature some of the highly ranked, innovative research from ISOQOL abstract submissions. All oral and poster abstract submissions are eligible for selection.
Plenary 3: Big data to support research and health care
Digital data capture is now commonplace in everyday life – from public and patients recording health data using apps and digital tracking devices to consumer data from our online purchases. Key questions are whether and how these data can be brought together to improve health and the implications of data sharing for personal privacy and citizenship. In this plenary, we explore the opportunities and challenges that big data brings.
Plenary 4: Generalizability of validity data across diseases and treatment settings: when is enough, enough?
This past two years has seen a trend toward recognizing that a given HRQoL questionnaire that measures a common and reasonably well-defined concept can be regarded as valid, and even “fit for purpose” if it has been tested and proven valid in many settings and diseases, but not necessarily the proposed new disease. In this plenary, we consider what the use of PROs in the digital age means for the concept of validity and how we apply PROs in drug development and trials.
Joanne Greenhalgh, PhD
University of Leeds
Leeds, United Kingdom
Diana Rofail, PhD CPsychol
Roche Products Limited
Welwyn Garden City, United Kingdom